A new self: MHC-class-I-independent natural-killer-cell self-tolerance

Nature Reviews Immunology

Volumn 5, Issue 5, 2005, Pages 363-374

  Kumar, Vinay ^a   McNerney, Megan E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECEPTOR;

ALLOIMMUNITY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CELL PROTECTION; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFECTION; LIGAND BINDING; LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; AUTOIMMUNITY; CELL ADHESION MOLECULES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LECTINS; RECEPTORS, ANTIGEN; SELF TOLERANCE; SIALIC ACIDS;

EID: 18844413022     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1603     Document Type: Review

References (138)

1. Stetson, D. B. et al. Constitutive cytokine mRNAs mark natural killer (NK) and NKT cells poised for rapid effector function. J. Exp. Med. 198, 1069-1076 (2003).
2. Tato, C. M. et al. Innate production of IFN-γ by NK cells is independent of epigenetic modification of the IFN-γ promoter. J. Immunol. 173, 1514-1517 (2004).
3. Walker, L. S. & Abbas, A. K. The enemy within: keeping self-reactive T cells at bay in the periphery. Nature Rev. Immunol. 2, 11-19 (2002).
4. Raulet, D. H., Vance, R. E. & McMahon, C. W. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19, 291-330 (2001).
5. Karre, K., Ljunggren, H. G., Piontek, G. & Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675-678 (1986).
6. Tay C. H., Szomolanyi-Tsuda, E. & Welsh, R. M. Control of infections by NK cells. Curr. Top. Microbiol Immunol. 230, 193-220 (1998).
7. Yu, Y. Y., Kumar, V. & Bennett, M. Murine natural killer cells and marrow graft rejection. Annu. Rev. Immunol. 10, 189-213 (1992).
8. Lanier, L. L. NK cell recognition. Annu. Rev. Immunol. 23, 225-274 (2005).
9. Vance, R. E., Kraft, J. R., Altman, J. D., Jensen, P. E. & Raulet, D. H. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1°. J. Exp. Med. 188, 1841-1848 (1998).
10. Lee, N. et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl Acad. Sci. USA 95, 5199-5204 (1998).
11. Braud, V. M. et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795-799 (1998).
12. Chapman, T. L., Heikeman, A. P. & Bjorkman, P. J. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 11, 603-613 (1999).
13. Liao, N. S., Bix, M., Zijlstra, M., Jaenisch, R. & Raulet, D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 253, 199-202 (1991).
14. - bone marrow in chimeric mice. Proc. Natl Acad. Sci. USA 88, 10332-10336 (1991).
15. de la Salle, H. et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency Science 265, 237-241 (1994).
16. Zimmer, J. et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J. Exp. Med. 187, 117-122 (1998).
17. - mice. J. Immunol. 159, 5219-5225 (1997).
18. Salcedo, M. et al. Fine tuning of natural killer cell specificity and maintenance of self tolerance in MHC class I-deficient mice. Eur. J. Immunol. 28, 1315-1321 (1998).
19. Market, G. et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 103, 1770-1778 (2004). This study shows that increased CEACAM1 expression prevents NK-cell autoreactivity in TAP2-deficient patients.
20. Vitale, M. et al. Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells. Blood 99, 1723-1729 (2002). This paper shows that triggering receptors in TAP2-deficient patients are functional, and the authors suggest a role for non-MHC-binding inhibitory receptors in self-tolerance.
21. 2-microglobulin-deficient mice. J. Immunol. 169, 126-136 (2002).
22. Fernandez, N. C. et al. A subset of natural killer cells achieve setf-tolerance without expressing inhibitory receptors specific for self MHC molecules. Blood 22 Feb 2005 (doi:10.1182/blood-2004-1108-3156).
23. Yu, Y. Y. et al. The role of Ly49A and 5E6 (Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity 4, 67-76 (1996).
24. Liu, J. et al. Ly49I NK cell receptor transgene inhibition of rejection of H2° mouse bone marrow transplants. J. Immunol. 164, 1793-1799 (2000).
25. - cells: a possible mechanism of tolerance during NK cell development. J. Immunol. 162, 6975-6980 (1999).
26. Dorfman, J. R. & Raulet, D. H. Acquisition of Ly49 receptor expression by developing natural killer cells. J. Exp. Med. 187, 609-618 (1998).
27. Vance, R. E., Jamieson, A. M., Cado, D. & Raulet, D. H. Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation. Proc. Natl Acad. Sci. USA 99, 868-873 (2002).
28. Sivori, S, et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc. Natl Acad. Sci. USA 99, 4526-4531 (2002).
29. Lee, K. M. et al. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J. Exp. Med. 199, 1245-1254 (2004). This paper, together with references 38 and 39, characterizes 2B4-deficient mice, showing that 2B4 inhibits NK cells and that this outcome is not regulated by SAP.
30. Boles, K. S., Stepp, S. E., Bennett, M., Kumar, V. & Mathew, P. A. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol. Rev. 181, 234-249 (2001).
31. Kubota, K. A structurally variant form of the 2B4 antigen is expressed on the cell surface of mouse mast cells. Microbiol. Immunol. 46, 589-592 (2002).
32. Munitz, A, et al. 2B4 (CD244) Is expressed and functional on human eosinophils. J. Immunol. 174, 110-118 (2005).
33. + T cells. Mol. Immunol. 42, 489-494 (2005).
34. Engel, P., Eck, M. J. & Terhorst, C, The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nature Rev. Immunol. 3, 813-821 (2003).
35. Brown, M. H. et al. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J. Exp. Med. 188, 2083-2090 (1998).
36. Valiante, N. M. & Trinchieri, G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J. Exp. Mad. 178, 1397-1406 (1993).
37. Garni-Wagner, B. A., Purohit, A., Mathew, P. A., Bennett, M. & Kumar, V. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J. Immunol. 151, 60-70 (1993).
38. Mooney, J. M. et al. The murine NK receptor 2B4 (CD244) exhibits inhibitory function independent of signaling lymphocytic activation molecule-associated protein expression. J. Immunol. 173, 3953-3961 (2004).
39. Vaidya, S. V. et al. Targeted disruption of the 264 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J. Immunol. 174, 800-607 (2005).
40. Lee, K. M. et al. The NK cell receptor 2B4 augments antigen-specific T cell cytotoxicity through CD48 ligation on neighboring T cells. J. Immunol. 170, 4881-4885 (2003).
41. Assarsson, E. et al. NK cells stimulate proliferation of T and NK cells through 2B4/CD48 interactions. J. Immunol. 173, 174-180 (2004).
42. + T cell proliferation by 2B4/CD48 interactions. J. Immunol. 167, 6706-6710 (2001).
43. Tangye, S. G., Phillips, J. H., Lanier, L. L. & Nichols, K. E. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J. Immunol. 165, 2932-2936 (2000).
44. Tangye, S. G., Cherwinski, H., Lanier, L. L. & Phillips, J. H. 2B4-mediated activation of human natural killer cells. Mol. Immunol. 37, 493-501 (2000).
45. Parolini, S. et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. Med. 192, 337-346 (2000).
46. Glimcher, L., Shen, F. W. & Cantor, H. Identification of a cell-surface antigen selectively expressed on the natural killer cell. J. Exp. Med. 143, 1-9 (1977).
47. Koo, G. C. & Peppard, J. R. Establishment of monoclonal anti-NK-1.1 antibody. Hybridoma 3, 301-303 (1984).
48. - T cells. J. Exp. Med. 186, 1957-1963 (1997).
49. Carlyle, J. R. et al. Mouse NKR-P1B, a novel NK1.1 antigen with inhibitory function. J. Immunol. 162, 5917-5923 (1999).
50. Kung, S. K., Su, R. C., Shannon, J. & Miller, R. G. The NKR-P1B gene product is an inhibitory receptor on SJL/J NK cells. J. Immunol. 162, 5876-5887 (1999).
51. Iizuka, K., Naidenko, O. V., Plougastel, B. F., Fremont, D. H. & Yokoyama, W. M. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nature Immunol. 4, 801-807 (2003).
52. Carlyle, J. R. et al. Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc. Natl Acad. Sci. USA 101, 3527-3532 (2004). References 51 and 52 identify CLRs as ligands for receptors of the NKR-P1 family.
53. Lanier, L. L., Chang, C. & Phillips, J. H. Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J. Immunol. 153, 2417-2428 (1994).
54. Yokoyama, W. M. & Plougastel, B, F. Immune functions encoded by the natural killer gene complex. Nature Rev. Immunol. 3, 304-316 (2003).
55. Zhou, H, et al. A novel osteoblast-derived C-type lectin that inhibits osteoclast formation. J. Biol. Chem. 276, 14916-14923 (2001).
56. Plougastel, B., Dubbelde, C. & Yokoyama, W. M. Cloning of Clr, a new family of lectin-like genes localized between mouse Nkrp1a and Cd69. Immunogenetics 53, 209-214 (2001).
57. Boles, K. S., Barten, R., Kumaresan, P. R., Trowsdale, J. & Mathew, P. A. Cloning of a new lectin-like receptor expressed on human NK cells. Immunogenetics 50, 1-7 (1999).
58. Mathew, P. A. et al. The LLT1 receptor induces IFN-γ production by human natural killer cells. Mol. Immunol. 40, 1157-1163 (2004).
59. Hammarstrom, S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9, 67-81 (1999).
60. Moller, M. J., Kammerer, R., Grunert, F. & von Kleist, S. Biliary glycoprotein (BGP) expression on T cells and on a natural-killer-cell sub-population. Int. J. Cancer 65, 740-745 (1996).
61. Markel, G. et al. The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells. J. Immunol. 173, 3732-3739 (2004).
62. Singer, B. B. et al. Carcinoembryonic antigen-related cell adhesion molecule 1 expression and signaling in human, mouse, and rat leukocytes: evidence for replacement of the short cytoplasmic domain isoform by glycosylphosphatidylinositol-linked proteins in human leukocytes. J. Immunol. 168, 5139-5146 (2002).
63. Kammerer, R., Stober, D., Singer, B. B., Obrink, B. & Reimann, J. Carcinoembryonic antigen-related cell adhesion molecule 1 on murine dendritic cells is a potent regulator of T cell stimulation. J. Immunol. 166, 6537-6544 (2001).
64. Markel, G. et al. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J. Immunol. 168, 2803-2810(2002). This was one of the first reports on the inhibition of NK cells by CEACAM1, which led to much further research.
65. Markel, G, et al. Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients. Eur. J. Immunol. 34, 2138-2148 (2004).
66. Svenberg T, et al. Serum level of biliary glycoprotein I, a determinant of cholestasis, of similar use as γ-glutamyltranspeptidase. Scand. J. Gastroenterol. 16, 817-824 (1981).
67. Crocker, P. R. & Varki, A. Siglecs, sialic acids and innate immunity. Trends Immunol. 22, 337-342 (2001).
68. Angata, T. & Varki, A. Chemical diversity in the sialic acids and related α-keto acids: an evolutionary perspective. Chem. Rev. 102, 439-469 (2002).
69. Falco, M. et al. Identification and molecular cloning of P75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J. Exp. Med. 190, 793-802 (1999).
70. Nicoll, G. et al. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J. Biol. Chem. 274, 34089-34095 (1999).
71. Ito, A., Handa, K., Withers, D. A., Satoh, M. & Hakomori, S. Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression. FEBS Lett. 504, 82-86 (2001).
72. Yamaji, T., Teranishi, T., Alphey, M. S., Crocker, P. R. & Hashimoto, Y. A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to α2,8-disialyl and branched α2,6-sialyl residues. A comparison with Siglec-9. J. Biol. Chem. 277, 6324-6332 (2002).
73. Nicoll, G, et al. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur. J. Immunol. 33, 1642-1648 (2003). This paper shows that GD3 expression by target cells inhibits NK cells through interaction with SIGLEC7.
74. Urmacher, C., Cordon-Cardo, C. & Houghton, A. N. Tissue distribution of GD3 ganglioside detected by mouse monoclonal antibody R24. Am. J. Dermatopathol. 11, 577-581 (1989).
75. Kniep, B., Flegel, W. A., Northoff, H. & Rieber, E. P. CDw60 glycolipid antigens of human leukocytes: structural characterization and cellular distribution. Blood 82, 1776-1786 (1993).
76. Ikehara, Y., Ikehara, S. K. & Paulson, J. C. Negative regulation of T cell receptor signaling by Sigfec-7 (p70/ AIRM) and Siglec-9. J. Biol. Chem. 279, 43117-13125 (2004).
77. Avril, T., Floyd, H., Lopez, F., Vivier, E. & Crocker, P. R. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by siglecs-7 and -9, CD33-related siglecs expressed on human monocytes and NK cells. J. Immunol. 173, 6841-6849 (2004).
78. Zhang, J, Q., Nicoll, G., Jones, C. & Crocker, P. R. Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J. Biol. Chem. 275, 22121-22126 (2000).
79. Zhang, J. Q., Biedermann, B., Nitschke, L. & Crocker, P. R. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur. J. Immunol. 34, 1175-1184 (2004).
80. Ulyanova, T., Shah, D. D. & Thomas, M. L. Molecular cloning of MIS, a myeloid inhibitory siglec, that binds protein-tyrosine phosphatases SHP-1 and SHP-2. J. Biol. Chem. 276, 14451-14458 (2001).
81. van den Berg, T. K., Yoder, J. A. & Litman, G. W. On the origins of adaptive immunity: innate immune receptors join the tale. Trends Immunol. 25, 11-16 (2004).
82. Piccio, L. et al. Adhesion of human T cells to antigen-presenting cells through SIRPβ2-CD47 interaction costimulates T cell proliferation. Blood 105, 2421-2427 (2005).
83. Brooke, G., Holbrook, J. D., Brown, M. H. & Barclay, A. N. Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. J. Immunol. 173, 2562-2570 (2004).
84. Oldenburg, P.-A. et al. Role of CD47 as a marker of self on red blood cells. Science 288, 2051-2054 (2000).
85. Blazar, B. R. et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J. Exp. Med. 194, 541-550 (2001).
86. Katz, H. R. Inhibitory receptors and allergy. Curr. Opin. Immunol. 14, 698-704 (2002).
87. Wang, L. L., Mehta, I. K., LeBlanc, P. A. & Yokoyama, W. M. Mouse natural killer cells express gp49B1, a structural homologue of human killer inhibitory receptors. J. Immunol. 158, 13-17 (1997).
88. Wang, L. L., Chu, D. T., Dokun, A. O. & Yokoyama, W. M. Inducible expression of the gp49B inhibitory receptor on NK cells. J. Immunol. 164, 5215-5220 (2000).
89. 3 interaction inhibits antigen-induced mast cell activation. Nature Immunol. 2, 436-442 (2001).
90. 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61, ii96-ii99 (2002).
91. Rojo, S. et al. Natural killer cells and mast cells from gp49B null mutant mice are functional. Mol. Cell. Biol. 20, 7178-7182 (2000).
92. Gu, X. et al. The gp49B1 inhibitory receptor regulates the IFN-γ responses of T cells and NK cells. J. Immunol. 170, 4095-4101 (2003). This study shows that, compared with cells from normal mice, gp49B1-deficient NK cells and T cells produce more IFN-γ ex vivo, following in vivo viral infection.
93. Abramson, J., Xu, R. & Pecht, I. An unusual inhibitory receptor - the mast cell function-associated antigen (MAFA). Mol. Immunol. 38, 1307-1313 (2002).
94. Robbins, S. H. et al. Inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells. J. Immunol. 168, 2585-2589 (2002).
95. Corral, L., Hanke, T., Vance, R. E., Cado, D. & Raulet, D. H. NK cell expression of the killer cell lectin-like receptor G1 (KLRG1), the mouse homolog of MAFA, is modulated by MHC class I molecules. Eur. J. Immunol. 30, 920-930 (2000).
96. Meyaard, L. et al. LAIR-1, a novel inhibitory receptor expressed on human mononudear leukocytes. Immunity 7, 283-290 (1997).
97. Thorley-Lawson, D. A., Schooley, R. T., Bhan, A. K. & Nadler, L. M. Epstein-Barr virus superinduces 4 new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell 30, 415-425 (1982).
98. Biron, C. A., Byron, K. S. & Sullivan, J. L. Severe herpesvirus infections in an adolescent without natural killer cells N. Engl. J. Med. 320, 1731-1735 (1989).
99. Arase, H., Mocarski, E. S., Campbell, A. E., Hill, A. B. & Lanier, L. L. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296, 1323-1326 (2002).
100. Afonso, C. L. et al. The genome of fowlpox virus. J. Virol. 74, 3815-3831 (2000).
101. Shchelkunov, S. N. et al. The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins. Virology 243, 432-160 (1998).
102. Wilcock, D., Duncan, S. A., Traktman, P., Zhang, W. H. & Smith, G. L. The vaccinia virus A4OR gene product is a nonstructural, type II membrane glycoprotein that is expressed at the cell surface. J. Gen. Virol. 80, 2137-2148 (1999).
103. Cameron, C. et al. The complete DNA sequence of myxoma virus. Virology 264, 298-318 (1999).
104. Neilan, J. G. et al. An African swine fever virus ORF with similarity to C-type lectins is non-essential for growth in swine macrophages in vitro and for virus virulence in domestic swine. J. Gen. Virol. 80, 2693-2697 (1999).
105. Voigt, S., Sandford, G. R., Ding, L. & Burns, W. H. Identification and characterization of a spliced C-type lectin-like gene encoded by rat cytomegalovirus. J. Virol. 75, 603-611 (2001).
106. 3-dependent ligand binding. J. Cell Biol. 123, 485-496 (1993).
107. Campbell, I. G., Freemont, P. S., Foulkes, W. & Trowsdale, J. An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains. Cancer Res. 52, 5416-5420 (1992).
108. Tseng, C. T. & Kumpel, G. R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195, 43-49 (2002).
109. Crotta, S. et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 195, 35-41 (2002).
110. Razi, N. & Varki, A. Cryptic sialic acid binding lectins on human blood leukocytes can be unmasked by sialidase treatment or cellular activation. Glycobiology 9, 1225-1234 (1999).
111. Razi, N, & Varki, A. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc. Natl Acad. Sci. USA 95, 7469-7474 (1998).
112. Boulton, I. C. & Gray-Owen, S. D. Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4-T lymphocytes. Nature Immunol. 3, 229-236 (2002). This paper shows that the binding of bacteria to CEACAM1 at the surface of T cells inhibits T-cell functions.
113. Dveksler, G. S. et al. Several members of the mouse carcinoembryonic antigen-related glycoprotein family are functional receptors for the coronavirus mouse hepatitis virus-A59. J. Virol. 67, 1-8 (1993).
114. Virji, M., Watt, S. M., Barker, S., Makepeace, K. & Doyonnas, R. The N-domain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria meningitidis and Neisseria gonorrhoeae. Mol. Microbiol. 22, 929-939 (1996).
115. Leusch, H. G., Drzeniek, Z., Markos-Pusztai, Z. & Wagener, C. Binding of Escherichia coli and Salmonella strains to members of the carcinoembryonic antigen family: differential binding inhibition by aromatic α-glycosides of mannose. Infect Immun. 59, 2051-2057 (1991).
116. Hill, D. J. & Virji, M. A novel cell-binding mechanism of Moraxella catarrhalis ubiquitous surface protein UspA: specific targeting of the N-domain of carcinoembryonic antigen-related cell adhesion molecules by UspA1. Mol. Microbiol. 48, 117-129 (2003).
117. Virji, M. et al. Carcinoembryonic antigens are targeted by diverse strains of typable and non-typable Haemophilus Influenzae. Mol. Microbiol. 36, 784-795 (2000).
118. Garrido, F. et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18, 89-95 (1997).
119. Demanet, C. et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 103, 3122-3130 (2004).
120. Saito, S. et al. Expression of globe-series gangliosides in human renal cell carcinoma. Jpn J. Cancer Res. 88, 652-659 (1997).
121. Plunkett, T. A. & Ellis, P. A. CEACAM1: a marker with a difference or more of the same? J. Clin. Oncol. 20, 4273-4275 (2002).
122. Thies, A. et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J. Clin. Oncol. 20, 2530-2536 (2002).
123. Laack, E. et al. Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J. Clin. Oncol. 20, 4279-4284 (2002).
124. Kammerer, R. et al. The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma. J. Pathol. 204, 258-267 (2004).
125. Pende, D. et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the poliovirus receptor (CD155) and nectin-2 (CD112). Blood 105, 2066-2073 (2005).
126. Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002). This study shows the clinical benefits of NK-cell alloreactivity.
127. Moffett-King, A. Natural killer cells and pregnancy. Nature Rev. Immunol. 2, 656-663 (2002).
128. Markel, G. et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J. Clin. Invest. 110, 943-953 (2002).
129. Blazar, B. R. et al. A critical role for CD48 antigen in regulating alloengraftment and lymphohematopoietic recovery after bone marrow transplantation. Blood 92, 4453-1463 (1998).
130. Vitale, C. et al. Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation. Eur. J. Immunol. 34, 455-460 (2004).
131. Smith, G. M., Biggs, J., Morris, B., Anderson-Stewart, P. & Ward, R. Detection of a soluble form of the leukocyte surface antigen CD48 in plasma and its elevation in patients with lymphoid leukemias and arthritis. J. Clin. Immunol. 17, 502-509 (1997).
132. Wandstrat, A. E. et al. Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity 21, 769-780 (2004).
133. Speckman, R. A. et al. Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum. Genet. 112, 34-41 (2003).
134. Cantoni, C. et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur. J. Immunol. 29, 3148-3159 (1999)
135. Iijima, H. et al. Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1. J. Exp. Med. 199, 471-482 (2004).
136. Boulanger, L. M. & Shatz, C. J. Immune signalling in neural development, synaptic plasticity and disease. Nature Rev. Neurosci. 5, 521-531 (2004).
137. Malisan, F. & Testi, R. GD3 ganglioside and apoptosis. Biochim. Biophys. Acta 1585, 179-187 (2002).
138. Backstrom, E., Chambers, B. J., Kristensson, K. & Ljunggren, H. G. Direct NK cell-mediated lysis of syngenic dorsal root ganglia neurons in vitro. J. Immunol. 165, 4895-4900 (2000).